Catalent signs agreement for first-in-class oncological therapy

Zumutor Biologics has chosen Catalent to provide process optimisation and drug substance manufacturing services

picture of

Breaking News

GE Healthcare collaborates to develop ligands for AAV purification

Australian Children’s Medical Research Institute and GE have agreed to develop new affinity ligands for the ...

Audentes to join gene therapy hub in North Carolina with $109m facility

California-based biopharma will join the likes of Pfizer, Eli Lilly and Bluebird Bio with a 135,000 sqft gene therapy ...

BIA to commercialise novel elution method for viral vector purification

University of Zagreb in Coratia has signed an agreement to commercialise new method that helps preserve viruses during ...

Better by design: The role of delivery device in biosimilar adoption

George I’ons of Owen Mumford Pharmaceutical Services analyses the uptake of new biosimilars and their advancing ...

Catalent signs agreement for first-in-class oncological therapy

Zumutor Biologics has chosen Catalent to provide process optimisation and drug substance manufacturing services

Anteros enters the market powered by BioMotiv and Bristol-Myers Squibb

The biotech company focuses on developing new drugs for fibrotic and other inflammatory diseases

Medical cannabis made in Italy

Dr Fabio Di Francesco, a compounding pharmacist based in Rome, describes how cannabis is used in various dosage forms ...

Catalent adds to regenerative therapy portfolio with $315m acquisition

Belgian CDMO MaSTherCell Global is a technology-focused cell and gene therapy CDMO

MIT spinout designs gentle process for billions of engineered cells in minutes

Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect system using continuous fluid flow combined ...

Integrated solutions offer fast-track development for biopharmaceuticals

At the heart of any successful medicine launch is a robust manufacturing process that will reliably make the product in ...

Future market dynamics and opportunities in immuno-oncology

Long-term survival, tumour-agnostic effects and the potential for cure in a fraction of patients are key catalysts ...

Optimising viral vector production for biologics

To overcome existing challenges in viral vector production, Belgium-based Univercells has worked to develop an ...

3i builds single-use bioprocessing platform using three acquisitions

The UK-based company has acquired Cellon, Silicone Altimex and TBL Performance Plastics to establish a platform serving ...

Genopis plans plasmid CDMO business launch

Helixmith US-based spinout has capitalised on its pDNA manufacturing experience with plans to launch a CDMO business